Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, its accompanied health benefits could be ameliorated with a gradual reduction in semaglutide. The investigators will study if a gradual reduction of semaglutide is associated with different heart risk profile and hormones involved in energy regulation as compared to immediate treatment cessation.

NCT Number	NCT07294950
Lead Sponsor	Mount Sinai Hospital, Canada Collaborators: Heart and Stroke Foundation of Canada
Conditions	Obesity (Disorder), Weight Change, Blood Pressure Monitoring, Appetite Regulation
Enrollment	98 participants
Start Date	2026-02-01
Primary Completion	2028-09 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-02-11